Friedrich, Rainer W., G. F. Molnar, Michael Schiebe, and A. the adaptation of neuromuscular function to low temperature Joffre Mercier. Protein kinase C is required for long-lasting synap- (Friedrich et al. 1994) as well as other, not yet identified, tic enhancement by the neuropeptide DRNFLRFamide in crayfish. functions.
J. Neurophysiol. 79: 1127 -1131 , 1998 In a previous study it was shown that inhibition of calneuropeptide AspArgAsnPheLeuArgPhe-NH 2 (DRNFLRFamide, cium/calmodulin-dependent protein kinase II (CaMK II) de-DF 2 ) induces a long-lasting enhancement of synaptic transmission lays the increase in excitatory postsynaptic potential (EPSP) at neuromuscular junctions on the crayfish deep abdominal extenamplitude induced by DF 2 at the neuromuscular junction but sor muscles. Here we investigated the function of protein kinase does not affect long-term synaptic enhancement (Noronha C (PKC) in this effect because PKC has been implied in the control and Mercier 1995) . The maintenance of synaptic enhanceof long-term synaptic modulation in other systems. The general kinase antagonist staurosporine reduced both the initial increase in ment by DF 2 therefore appears to be mediated by other sigexcitatory postsynaptic potential (EPSP) amplitude and the dura-naling systems. Here we have examined whether or not these tion of synaptic enhancement. Unlike staurosporine, the selective signaling systems involve protein kinase C (PKC), because PKC inhibitors, chelerythrine and bisindolylmaleimide, augmented PKC has been implicated in the control of long-term synaptic the initial EPSP increase. However, like staurosporine, they also modulation in some nonpeptidergic forms of synaptic modureduced the duration of synaptic enhancement. The PKC activator, lation (e.g. Bliss and Collingridge 1993; Byrne and Kandel phorbol-12-myristate 13-acetate, induced a long-lasting synaptic 1996; Dixon and Atwood 1989a,b). Pharmacological inhibienhancement that was blocked by chelerythrine. These results show tion of PKC abolished the maintenance but not the initial that synaptic enhancement by DF 2 is mediated by different intracelphase of synaptic enhancement by DF 2 , showing that PKC lular signaling systems that act in temporal sequence. The initial is required for long-lasting synaptic enhancement by DF 2 .
increase in EPSP amplitudes is negatively regulated by PKC and involves another, staurosporine-sensitive, kinase; whereas, the Preliminary results were published in abstract form maintenance of synaptic enhancement requires PKC. (Friedrich et al. 1993) .
M E T H O D S I N T R O D U C T I O N
Experiments were performed on the deep abdominal extensor Long-lasting changes in synaptic transmission underlie muscle L1 in segment 4 of the crayfish, Procambarus clarkii (2-important physiological and developmental processes such 4 cm carapace length). EPSPs in muscle cells were evoked by as learning, memory formation, and the establishment of electrical stimulation (0.1 or 0.2 Hz) of axon 3 in segment 3 and recorded intracellularly as described by Mercier and Atwood synaptic connections. In the temporal domain, long-term (1989) . EPSP amplitude was measured every 30 s and the values synaptic modulation can be separated into sequential phases averaged within 1.5-or 5-min time bins. All experiments were that are mediated by distinct intracellular signaling systems, performed in a perfused recording chamber at 8 { 0.3ЊC (SE) as found in model systems such as serotonin-induced facilitaexcept those involving phorbol-12-myristate 13-acetate (PMA), tion in crustaceans (Dixon and Atwood 1989a,b; Goy and which were perfomed in a static bath at 15 { 0.5ЊC for safety Kravitz 1989) extensor neuromuscular junction ). This
The following stock solutions were prepared and diluted into synaptic enhancement is the result of an increase in the saline directly before use: DF 2 (synthesized by T.S. Chen of the amount of transmitter released (Skerrett et al. 1995) . DF 2 , Biotechnology Service Centre, Toronto, Canada), 100 mM in water which belongs to the family of FMRFamide-related peptides or saline; PMA (Sigma), 1 mM in dimethyl sulfoxide (DMSO); (Price and Greenberg 1992) , also has cardioexcitatory ef-staurosporine (Sigma), 1 mM in DMSO; chelerythrine chloride fects and probably functions as a neurohormone, because it (LC Services Woburn, MA), 10 mM in water; and bisindolylis released into the circulation out any given experiment and did not exceed 0.1%, which had no effect in control experiments. Control recordings in the absence of DF 2 were carried out with each drug for an extended period of time to detect possible effects of the drug alone. None of the drugs used had an effect on the resting membrane potential. Statistical comparisons were performed by using a Mann-Whitney U test unless otherwise noted. Values are means { SE.
R E S U L T S
A 15-to 20-min application of 200 nM DF 2 elicited a long-lasting increase in EPSP amplitudes (Fig. 1A) that amounted, on average, to 146 { 12% (n Å 44). In three experiments, recordings were continued for 80 min after onset of DF 2 application. EPSPs were still elevated at that time, showing that synaptic enhancement outlasts DF 2 application by ú1 h.
Protein kinase inhibitors were used to identify components of the intracellular signaling systems that mediate synaptic enhancement by DF 2 . To analyze the effects of the inhibitors on the temporal development of synaptic enhancement independently from those on the maximum EPSP increase, the time courses of the EPSP increase induced by DF 2 were normalized to the maximum EPSP increase for each inhibitor and are compared in Fig. 1 . Effects of inhibitors on the maximum EPSP were analyzed separately and are expressed in Fig. 2 enhancement by DF 2 we used the broad spectrum kinase compared with EPSP increase in presence of staurosporine (stau: left, 100 antagonist staurosporine (Ruegg and Burgess 1989) . In the nM, n Å 8; right, 1 mM, n Å 9), chelerythrine (chel; 10 mM, n Å 8), and BIM (250 nM, n Å 6). Levels of significance: * P°0.05; *** P õ 0.0001. absence of DF 2 , staurosporine alone (100 nM or 1 mM)
01-28-98 10:30:50 neupa LP-Neurophys increase after 60 min; n Å 6, P õ 0.0001; Fig. 3 ). When preparations were treated first with PMA for 1-3 h, subsequent addition of 10 mM chelerythrine for 30-40 min decreased EPSPs by 34 { 10% of the amplitudes recorded at the end of exposure to PMA alone (n Å 3; data not shown). These data indicate that activation of PKC causes a longlasting synaptic enhancement, which is consistent with the effect of PKC on other synapses (Dixon and Atwood 1989a; Malinow et al. 1988; Nishizuka 1992; Shapira et al. 1987; Sugita et al. 1992 ) and with a role for PKC in the maintenance of synaptic enhancement by DF 2 .
D I S C U S S I O N
We have used the broad-spectrum kinase inhibitor, staurosporine, and the specific PKC antagonists, chelerythrine and Phorbol-12-myristate 13-acetate (PMA, 500 nM) was applied during period BIM, to examine the function of PKC in the long-lasting indicated by shaded area in absence (᭺; n Å 7) or presence (q; n Å 6) of synaptic enhancement induced by DF 2 at the crayfish neuro-10 mM chelerythrine. Chelerythrine alone was applied 30 min before addi-muscular junction. The specificity of chelerythrine and BIM tion of PMA.
for PKC is well established (Herbert et al. 1990; Toullec et al. 1991) and further supported by the following observations: 1) the effects of both inhibitors on synaptic enhanceslightly decreased EPSP amplitudes in 3 of 18 preparations, ment by DF 2 were very similar and 2) they do not affect although by not more than 5%. The EPSP increase induced the EPSP increase elicited by the protein kinase A (PKA) by DF 2 in the presence of 100 nM and 1 mM staurosporine activator, Sp-cAMPS, or by the adenylyl cyclase activator, was significantly reduced to 54 { 4% (n Å 8) and 43 { forskolin (M. M. Boldt, R. W. Friedrich, and A. J, Mercier, 5% (n Å 9), respectively, of the control increase obtained unpublished results). In the absence of DF 2 , chelerythrine in the absence of staurosporine (P õ 0.0001; Fig. 2 ). Fur-and staurosporine caused slight reductions in EPSP amplithermore, the peak EPSP increase occurred earlier than in tude. These may be nonspecific effects on synaptic transmisthe control and EPSP amplitudes subsequently declined sig-sion, but the underlying mechanisms are not clear. nificantly more rapidly ( Fig. 1B; 
analysis of variance
In the presence of each of the inhibitors used, the peak (ANOVA) followed by post hoc Scheffe's F test; P õ increase in EPSP amplitude induced by DF 2 occurred earlier 0.001), indicating that staurosporine inhibited the mainte-and the synaptic enhancement was less sustained. The magnance of synaptic enhancement.
nitude of the EPSP increase was reduced by staurosporine The PKC antagonists, chelerythrine and bisindolylmalei-but augmented by chelerythrine and BIM. These results mide (BIM), were used to determine the role(s) of PKC in show that PKC has a negative effect on the initial EPSP synaptic enhancement by DF 2 . These agents inhibit PKC by increase but is required for the maintenance of synaptic endifferent mechanisms and were shown not to affect other hancement by DF 2 . On the basis of these results, synaptic kinases at the concentrations used here (Herbert et al. 1990 ; enhancement by DF 2 can be dissociated into at least two Toullec et al. 1991) . Chelerythrine alone (10 mM) decreased phases: 1) an early phase that comprises the initial increase EPSP amplitudes in 10 of 14 preparations by an average of in EPSP amplitudes and is inhibited by staurosporine but 13 { 5% and EPSPs reached a stable level after 10-15 augmented by PKC antagonists and 2) a late phase that min. BIM alone (250 nM) had no effect. In contrast to comprises the maintenance of synaptic enhancement and is staurosporine, both chelerythrine and BIM increased the abolished by both staurosporine and PKC inhibitors. These maximum effect of DF 2 to 138 { 19% (n Å 8, P Å 0.05) phases are not obvious without pharmacological dissection and 154 { 25% (n Å 6, P õ 0.05), respectively, of the because no clearcut transition is apparent in the time course control EPSP increase (Fig. 2) . Like staurosporine, chel-of synaptic enhancement in the absence of inhibitors. erythrine and BIM shifted the peak EPSP increase to earlier
The increase in EPSP amplitude induced by DF 2 in the times and significantly reduced the duration of synaptic en-presence of either staurosporine or the PKC inhibitors hancement by DF 2 (Fig. 1, C and D; ANOVA followed by peaked within 10 min and thereafter declined while DF 2 was post hoc Scheffe's F test; P õ 0.001). These results indicate still present, indicating that the early phase is transient (total that PKC is necessary for the maintenance of synaptic en-duration°40 min). Without inhibitors, EPSP amplitudes hancement by DF 2 but has a negative effect on the initial increased asymptotically during the period of DF 2 applicaincrease in EPSP amplitudes. tion and thereafter remained elevated for at least 1 h. This The PKC-activator, PMA, was used to determine the ef-suggests that the late phase, which requires PKC, overlaps fect of PKC on synaptic transmission in the absence of DF 2 . with the early phase but progresses more slowly. This is PMA (500 nM) induced a progressive increase in EPSP consistent with the slow increase in EPSP amplitude induced amplitudes, which after 60 min amounted to 313 { 100% by PMA and with the time course of synaptic enhancement (n Å 7; Fig. 3 ) and could not be reversed by washing for in the presence of a CaMK II antagonist, which appears up to one hour. 10 mM chelerythrine almost completely to inhibit the early phase (Noronha and Mercier 1995; see below) . blocked the EPSP increase induced by PMA (32 { 21%
The early phase of synaptic enhancement by DF 2 was the signaling downstream of PKC, and the events that ultimately lead to modulation of synaptic function. antagonized by staurosporine but not by PKC inhibitors, indicating that it involves at least one kinase other than PKC. the early phase while the late phase is progressing, thereby FRIEDRICH, R. W., MERCIER, A. J., AND SCHIEBE, M. A crustacean regulating the transition between the two phases.
